Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 3, 2016, Pages 291-304

  Coates, Laura C ^a   FitzGerald, Oliver ^b   Helliwell, Philip S ^a   Paul, Carle ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Inflammation; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; APREMILAST; BARICITINIB; CORTICOSTEROID; CRISABOROLE; CYCLOSPORIN; ETANERCEPT; ETRETIN; FILGOTINIB; FUMARIC ACID; GOLIMUMAB; INFLIXIMAB; IXEKIZUMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PEFICITINIB; PICLIDENOSON; PONESIMOD; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB; ANTIRHEUMATIC AGENT; CYTOKINE;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; HUMAN; IMMUNOPATHOGENESIS; MALIGNANT NEOPLASTIC DISEASE; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; INFLAMMATION; MOLECULARLY TARGETED THERAPY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PSORIASIS;

EID: 85003633132     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.05.012     Document Type: Review

References (198)

1. [1] Helmick, C.G., Lee-Han, H., Hirsch, S.C., Baird, T.L., Bartlett, C.L., Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med 47:1 (2014), 37–45.
2. [2] Parisi, R., Symmons, D.P., Griffiths, C.E., Ashcroft, D.M., Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:2 (2013), 377–385.
3. [3] Lowes, M.A., Bowcock, A.M., Krueger, J.G., Pathogenesis and therapy of psoriasis. Nature 445:7130 (2007), 866–873.
4. [4] Nograles, K.E., Davidovici, B., Krueger, J.G., New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 29:1 (2010), 3–9.
5. [5] Schön, M.P., Boehncke, W.H., Psoriasis. N Engl J Med 352:18 (2005), 1899–1912.
6. [6] Menter, A., Gottlieb, A., Feldman, S.R., Van Voorhees, A.S., Leonardi, C.L., Gordon, K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:5 (2008), 826–850.
7. [7] Meyer, N., Paul, C., Feneron, D., Bardoulat, I., Thiriet, C., Camara, C., et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 24:9 (2010), 1075–1082.
8. [8] Rapp, S.R., Feldman, S.R., Exum, M.L., Fleischer, A.B. Jr, Reboussin, D.M., Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:3 Pt 1 (1999), 401–407.
9. [9] Chimenti, M.S., Ballanti, E., Perricone, C., Cipriani, P., Giacomelli, R., Perricone, R., Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 12:5 (2013), 599–606.
10. [10] Gottlieb, A., Korman, N.J., Gordon, K.B., Feldman, S.R., Lebwohl, M., Koo, J.Y., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:5 (2008), 851–864.
11. [11] Helliwell, P., Wright, V., Psoriatic arthritis: clinical features. Rheumatology, 1997, 6.21.1–6.21.8.
12. [12] Alamanos, Y., Voulgari, P.V., Drosos, A.A., Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 35:7 (2008), 1354–1358.
13. [13] Gelfand, J.M., Gladman, D.D., Mease, P.J., Smith, N., Margolis, D.J., Nijsten, T., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol, 53(4), 2005, 573.
14. [14] Gladman, D.D., Antoni, C., Mease, P., Clegg, D.O., Nash, P., Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64:suppl 2 (2005), ii14–ii17.
15. [15] Haroon, M., FitzGerald, O., Winchester, R., Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options. Psoriasis Targets Ther 3 (2013), 11–23.
16. [16] Lofvendahl, S., Theander, E., Svensson, A., Carlsson, K.S., Englund, M., Petersson, I.F., Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden—a population-based register study. PLoS One, 9(5), 2014, e98024.
17. [17] Prey, S., Paul, C., Bronsard, V., Puzenat, E., Gourraud, P.A., Aractingi, S., et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 24:suppl 2 (2010), 31–35.
18. [18] Strand, V., Sharp, V., Koenig, A.S., Park, G., Shi, Y., Wang, B., et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 71:7 (2012), 1143–1150.
19. [19] Alamanos, Y., Drosos, A.A., Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4:3 (2005), 130–136.
20. [20] Rudan, I., Sidhu, S., Papana, A., Meng, S.J., Xin-Wei, Y., Wang, W., et al. Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health, 5(1), 2015, 010409.
21. [21] Scott, D.L., Wolfe, F., Huizinga, T.W., Rheumatoid arthritis. Lancet 376:9746 (2010), 1094–1108.
22. [22] Haroon, N., Aggarwal, A., Lawrence, A., Agarwal, V., Misra, R., Impact of rheumatoid arthritis on quality of life. Mod Rheumatol 17:4 (2007), 290–295.
23. [23] Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M.H., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:1 (2014), 62–68.
24. [24] Wolfe, F., Michaud, K., Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum 61:5 (2009), 667–673.
25. [25] Apel, M., Uebe, S., Bowes, J., Giardina, E., Korendowych, E., Juneblad, K., et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum 65:5 (2013), 1224–1231.
26. [26] McAllister, K., Eyre, S., Orrego, S., Genetics of rheumatoid arthritis: GWAS and beyond. Open Cardiovasc Med J 3 (2011), 31–46.
27. [27] O'Rielly, D.D., Rahman, P., Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol 7:12 (2011), 718–732.
28. [28] Raychaudhuri, S., Recent advances in the genetics of rheumatoid arthritis. Curr Opin Rheumatol 22:2 (2010), 109–118.
29. [29] Tsoi, L.C., Spain, S.L., Knight, J., Ellinghaus, E., Stuart, P.E., Capon, F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44:12 (2012), 1341–1348.
30. [30] McInnes, I., Schett, G., The pathogenesis of rheumatoid arthritis. N Engl J Med 365:23 (2011), 2205–2219.
31. [31] Thaler KJ, Gartlehner G, Kien C, Van Noord MG, Thakurta S, Wines RCM, et al. Drug Class Review: Targeted Immune Modulator. Final Update 3 Report. Prepared by the RTI-UNC Evidence-Based Practice Center for the Drug Effectiveness Review Project. Portland, OR: Oregon Health & Science University.. 〈http://derp.ohsu.edu/about/final-document-display.cfm〉 Accessed 11.09.15.
32. [32] Chen, Z., OʼShea, J.J., Th17 cells: a new fate for differentiating helper T cells. Immunol Res 41:2 (2008), 87–102.
33. [33] Dass, S., Vital, E.M., Emery, P., Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 56:8 (2007), 2715–2718.
34. [34] Gaffen, S.L., Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:8 (2009), 556–567.
35. [35] Johnson-Huang, L.M., Lowes, M.A., Krueger, J.G., Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 5:4 (2012), 423–433.
36. [36] Michalak-Stoma, A., Pietrzak, A., Szepietowski, J.C., Zalewska-Janowska, A., Paszkowski, T., Chodorowska, G., Cytokine network in psoriasis revisited. Eur Cytokine Netw 22:4 (2011), 160–168.
37. [37] Nakae, S., Iwakura, Y., Suto, H., Galli, S.J., Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81:5 (2007), 1258–1268.
38. [38] Perera, G.K., Di Meglio, P., Nestle, F.O., Psoriasis. Annu Rev Pathol 7 (2012), 385–422.
39. [39] Yanaba, K., Kamata, M., Ishiura, N., Shibata, S., Asano, Y., Tada, Y., et al. Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. J Leukoc Biol 94:4 (2013), 563–573.
40. [40] Kagami, S., Rizzo, H.L., Lee, J.J., Koguchi, Y., Blauvelt, A., Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130:5 (2010), 1373–1383.
41. [41] Zaba, L.C., Fuentes-Duculan, J., Eungdamrong, N.J., Abello, M.V., Novitskaya, I., Pierson, K.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129:1 (2009), 79–88.
42. [42] Fitzgerald, O., Winchester, R., Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther, 11(1), 2009, 214.
43. [43] Choy, E., Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford), 51(suppl 5), 2012 v3–11.
44. [44] O'Rielly, D.D., Rahman, P., Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol 28:5 (2014), 673–685.
45. [45] Hebert, H.L., Ali, F.R., Bowes, J., Griffiths, C.E., Barton, A., Warren, R.B., Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 166:3 (2012), 474–482.
46. [46] Duffin, K.C., Krueger, G.G., Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 129:4 (2009), 827–833.
47. [47] Oka, A., Mabuchi, T., Ozawa, A., Inoko, H., Current understanding of human genetics and genetic analysis of psoriasis. J Dermatol 39:3 (2012), 231–241.
48. [48] Girolomoni, G., Mrowietz, U., Paul, C., Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167:4 (2012), 717–724.
49. [49] Castelino, M., Barton, A., Genetic susceptibility factors for psoriatic arthritis. Curr Opin Rheumatol 22:2 (2010), 152–156.
50. [50] Yamamoto, T., Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol 21:5 (2011), 660–666.
51. [51] van Kuijk, A.W., Reinders-Blankert, P., Smeets, T.J., Dijkmans, B.A., Tak, P.P., Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 65:12 (2006), 1551–1557.
52. [52] Sabat, R., Philipp, S., Höflich, C., Kreutzer, S., Wallace, E., Asadullah, K., et al. Immunopathogenesis of psoriasis. Exp Dermatol 16:10 (2007), 779–798.
53. [53] Wolk, K., Haugen, H.S., Xu, W., Witte, E., Waggie, K., Anderson, M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 87:5 (2009), 523–536.
54. [54] Belasco, J., Louie, J.S., Gulati, N., Wei, N., Nograles, K., Fuentes-Duculan, J., et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol 67:4 (2015), 934–944.
55. [55] Fitzgerald, O., Haroon, M., Giles, J.T., Winchester, R., Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther, 17(1), 2015, 115.
56. [56] Mohan, V.K., Ganesan, N., Gopalakrishnan, R., Association of susceptible genetic markers and autoantibodies in rheumatoid arthritis. J Genet 93:2 (2014), 597–605.
57. [57] Rommel, C., Camps, M., Ji, H., PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?. Nat Rev Immunol 7:3 (2007), 191–201.
58. [58] Husni, M.E., Mease, P.J., Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 12:4 (2010), 281–287.
59. [59] Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:10 (2005), 1421–1426.
60. [60] Ji, J., Shu, X., Sundquist, K., Sundquist, J., Hemminki, K., Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 100:9 (2009), 1499–1502.
61. [61] Pouplard, C., Brenaut, E., Horreau, C., Barnetche, T., Misery, L., Richard, M.A., et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 27:suppl 3 (2013), 36–46.
62. [62] Golpour, M., Hosseini, S.H., Khademloo, M., Ghasemi, M., Ebadi, A., Koohkan, F., et al. Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study. Dermatol Res Pract, 2012, 381905.
63. [63] Armstrong, E.J., Harskamp, C.T., Armstrong, A.W., Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc, 2(2), 2013, e000062.
64. [64] Gladman, D.D., Ang, M., Su, L., Tom, B.D., Schentag, C.T., Farewell, V.T., Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:7 (2009), 1131–1135.
65. [65] Horreau, C., Pouplard, C., Brenaut, E., Barnetche, T., Misery, L., Cribier, B., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 27:suppl 3 (2013), 12–29.
66. [66] Mehta, N.N., Yu, Y.D., Pinnelas, R., Krishnamoorthy, P., Shin, D.B., Troxel, A.B., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:8 (2011), 775.e1–775.e6.
67. [67] Prey, S., Paul, C., Bronsard, V., Puzenat, E., Gourraud, P.A., Aractingi, S., et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 24:suppl 2 (2010), 23–30.
68. [68] Solomon, D.H., Goodson, N.J., Katz, J.N., Weinblatt, M.E., Avorn, J., Setoguchi, S., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65:12 (2006), 1608–1612.
69. [69] Miele, L., Vallone, S., Cefalo, C., La Torre, G., Di Stasi, C., Vecchio, F.M., et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:4 (2009), 778–786.
70. [70] Bhole, V.M., Choi, H.K., Burns, L.C., Vera, K.C., Lacaille, D.V., Gladman, D.D., et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 51:3 (2012), 552–556.
71. [71] Ogdie, A., Yu, Y., Haynes, K., Love, T.J., Maliha, S., Jiang, Y., et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74:2 (2015), 326–332.
72. [72] Ahlehoff, O., Gislason, G.H., Charlot, M., Jørgensen, C.H., Lindhardsen, J., Olesen, J.B., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270:2 (2011), 147–157.
73. [73] Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 296:14 (2006), 1735–1741.
74. [74] Gelfand, J.M., Dommasch, E.D., Shin, D.B., Azfar, R.S., Kurd, S.K., Wang, X., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 129:10 (2009), 2411–2418.
75. [75] Channual, J., Wu, J.J., Dann, F.J., Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 22:1 (2009), 61–73.
76. [76] Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:3 (2015), 480–489.
77. [77] Armstrong, A.W., Brezinski, E.A., Follansbee, M.R., Armstrong, E.J., Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:4 (2014), 500–512.
78. [78] Hugh, J., Van Voorhees, A.S., Nijhawan, R.I., Bagel, J., Lebwohl, M., Blauvelt, A., et al. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 70:1 (2014), 168–177.
79. [79] Gisondi, P., Farina, S., Giordano, M.V., Girolomoni, G., Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol 106:12 (2010), 1754–1757.
80. [80] Michaud, K., Wolfe, F., Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:5 (2007), 885–906.
81. [81] Lindhardsen, J., Ahlehoff, O., Gislason, G.H., Madsen, O.R., Olesen, J.B., Svendsen, J.H., et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. Br Med J, 344, 2012, e1257.
82. [82] Panoulas, V.F., Douglas, K.M., Milionis, H.J., Stavropoulos-Kalinglou, A., Nightingale, P., Kita, M.D., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46:9 (2007), 1477–1482.
83. [83] Maradit-Kremers, H., Nicola, P.J., Crowson, C.S., Ballman, K.V., Gabriel, S.E., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:3 (2005), 722–732.
84. [84] Stern, R.S., Nichols, K.T., Vakeva, L.H., Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 336:15 (1997), 1041–1045.
85. [85] Paul, C.F., Ho, V.C., McGeown, C., Christophers, E., Schmidtmann, B., Guillaume, J.C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5-y cohort study. J Invest Dermatol 120:2 (2003), 211–216.
86. [86] Stern, R.S., Laird, N., Melski, J., Parrish, J.A., Fitzpatrick, T.B., Bleich, H.L., Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 310:18 (1984), 1156–1161.
87. [87] Kimball, A.B., Schenfeld, J., Accortt, N.A., Anthony, M.S., Rothman, K.J., Pariser, D., Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005–09. Br J Dermatol 170:2 (2014), 366–373.
88. [88] Rohekar, S., Tom, B.D., Hassa, A., Schentag, C.T., Farewell, V.T., Gladman, D.D., Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58:1 (2008), 82–87.
89. [89] Wong, K., Gladman, D.D., Husted, J., Long, J.A., Farewell, V.T., Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40:10 (1997), 1868–1872.
90. [90] Mellemkjaer, L., Linet, M.S., Gridley, G., Frisch, M., Moller, H., Olsen, J.H., Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:10 (1996), 1753–1757.
91. [91] Chen, Y.J., Wu, C.Y., Chen, T.J., Shen, J.L., Chu, S.Y., Wang, C.B., et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 65:1 (2011), 84–91.
92. [92] Marcil, I., Stern, R.S., Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358:9287 (2001), 1042–1045.
93. [93] Nijsten, T.E., Stern, R.S., The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 121:2 (2003), 252–258.
94. [94] Stern, R.S., Lange, R., Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 91:2 (1988), 120–124.
95. [95] Stern, R.S., Liebman, E.J., Vakeva, L., Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 90:17 (1998), 1278–1284.
96. [96] Wenk, K.S., Arrington, K.C., Ehrlich, A., Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 25:4 (2011), 383–391.
97. [97] Gisondi, P., Targher, G., Zoppini, G., Girolomoni, G., Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:4 (2009), 758–764.
98. [98] Madanagobalane, S., Anandan, S., The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 53:3 (2012), 190–197.
99. [99] Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346:16 (2002), 1221–1231.
100. [100] Ruderman, E.M., Crawford, J.M., Maier, A., Liu, J.J., Gravallese, E.M., Weinblatt, M.E., Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 36:2 (1997), 210–213.
101. [101] Bhambhani N, Amin M, Gutierrez J, Cuparri G, Disla E. Prevalence of non-alcoholic fatty liver disease in rheumatoid arthritis. Poster 360 Presented at the American College of Rheumatology; 2006.
102. [102] Boehncke, W.H., Gladman, D.D., Chandran, V., Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol 38:3 (2011), 567–571.
103. [103] Peters, M.J., Symmons, D.P., McCarey, D., Dijkmans, B.A., Nicola, P., Kvien, T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:2 (2010), 325–331.
104. [104] Dauden, E., Castaneda, S., Suarez, C., Garcia-Campayo, J., Blasco, A.J., Aguilar, M.D., et al. Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities. Actas Dermosifiliogr 103:suppl 1 (2012), 1–64.
105. [105] Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Kremer, J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:5 (2012), 625–639.
106. [106] Kremer, J.M., Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:1 (1999), 14–26.
107. [107] Kirwan, J., Power, L., Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheumatol 19:3 (2007), 233–237.
108. [108] Ben-Zvi, I., Kivity, S., Langevitz, P., Shoenfeld, Y., Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:2 (2012), 145–153.
109. [109] Greenstein, R.J., Su, L., Shahidi, A., Brown, S.T., On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis. PLoS One, 2(6), 2007, e516.
110. [110] Tai, K., Iwasaki, H., Ikegaya, S., Ueda, T., Minocycline modulates cytokine and chemokine production in lipopolysaccharide-stimulated THP-1 monocytic cells by inhibiting IkappaB kinase alpha/beta phosphorylation. Transl Res 161:2 (2013), 99–109.
111. [111] Leitner, J., Drobits, K., Pickl, W.F., Majdic, O., Zlabinger, G., Steinberger, P., The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunol Lett 140:1–2 (2011), 74–80.
112. [112] Lee, C.S., Li, K., A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf 8:6 (2009), 769–779.
113. [113] Rostami, Y.M., Mrowietz, U., Fumaric acid esters. Clin Dermatol 26:5 (2008), 522–526.
114. [114] Schafer, P.H., Parton, A., Capone, L., Cedzik, D., Brady, H., Evans, J.F., et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 26:9 (2014), 2016–2029.
115. [115] Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:4 (2014), 326–338.
116. [116] Waldburger, J.M., Firestein, G.S., Garden of therapeutic delights: new targets in rheumatic diseases. Arthritis Res Ther, 11(1), 2009, 206.
117. [117] Leonardi, C.L., Powers, J.L., Matheson, R.T., Goffe, B.S., Zitnik, R., Wang, A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:21 (2003), 2014–2022.
118. [118] Zaba, L.C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suarez-Farinas, M., Fuentes-Duculan, J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204:13 (2007), 3183–3194.
119. [119] Caproni, M., Antiga, E., Melani, L., Volpi, W., Del Bianco, E., Fabbri, P., Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:2 (2009), 210–214.
120. [120] Bedini, C., Nasorri, F., Girolomoni, G., Pita, O., Cavani, A., Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 157:2 (2007), 249–258.
121. [121] Marble, D.J., Gordon, K.B., Nickoloff, B.J., Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 48:2 (2007), 87–101.
122. [122] Leonardi, C.L., Kimball, A.B., Papp, K.A., Yeilding, N., Guzzo, C., Wang, Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:9625 (2008), 1665–1674.
123. [123] Papp, K.A., Langley, R.G., Lebwohl, M., Krueger, G.G., Szapary, P., Yeilding, N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:9625 (2008), 1675–1684.
124. [124] Tausend, W., Downing, C., Tyring, S., Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 18:3 (2014), 156–169.
125. [125] Novartis. Novartis Announces FDA Approval for First IL-17A Antagonist Cosentyx(TM) (secukinumab) for Moderate-to-Severe Plaque Psoriasis Patients. 〈https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab.〉 Accessed 30.09.15.
126. [126] Fagerli, K.M., Lie, E., van der Heijde, D., Heiberg, M.S., Lexberg, A.S., Rodevand, E., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73:1 (2014), 132–137.
127. [127] Ash, Z., Gaujoux-Viala, C., Gossec, L., Hensor, E.M., Fitzgerald, O., Winthrop, K., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71:3 (2012), 319–326.
128. [128] Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I.B., Puig, L., Li, S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:6 (2014), 990–999.
129. [129] Wittmann, M., Helliwell, P.S., Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) 3:1 (2013), 1–15.
130. [130] UK Medicines Information. New Drugs Online Report for Ustekinumab. 〈http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=467〉. Accessed 20.06.14.
131. [131] Wofford, J., Menter, A., Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 10:2 (2014), 189–202.
132. [132] Ursini, F., Naty, S., Russo, E., Grembiale, R.D., Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother 4:suppl 1 (2013), S29–S32.
133. [133] Capsoni, F., Sarzi-Puttini, P., Atzeni, F., Minonzio, F., Bonara, P., Doria, A., et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res Ther 7:2 (2005), R250–R255.
134. [134] Schramm, R., Thorlacius, H., Neutrophil recruitment in mast cell-dependent inflammation: inhibitory mechanisms of glucocorticoids. Inflamm Res 53:12 (2004), 644–652.
135. [135] Ruderman, E.M., Pope, R.M., More than just B-cell inhibition. Arthritis Res Ther, 13(4), 2011, 125.
136. [136] Baier, G., Wagner, J., PKC inhibitors: potential in T cell-dependent immune diseases. Curr Opin Cell Biol 21:2 (2009), 262–267.
137. [137] Hueber, A.J., McInnes, I.B., Immune regulation in psoriasis and psoriatic arthritis—recent developments. Immunol Lett 114:2 (2007), 59–65.
138. [138] Lee, J.K., Kim, S.H., Lewis, E.C., Azam, T., Reznikov, L.L., Dinarello, C.A., Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci USA 101:23 (2004), 8815–8820.
139. [139] Mavers, M., Ruderman, E.M., Perlman, H., Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep 11:5 (2009), 378–385.
140. [140] O'Sullivan, L.A., Liongue, C., Lewis, R.S., Stephenson, S.E.M., Ward, A.C., Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 44:10 (2007), 2497–2506.
141. [141] Raychaudhuri, S.K., Raychaudhuri, S.P., Scid mouse model of psoriasis: a unique tool for drug development of autoreactive T-cell and th-17 cell-mediated autoimmune diseases. Indian J Dermatol 55:2 (2010), 157–160.
142. [142] Roussel, L., Houle, F., Chan, C., Yao, Y., Berube, J., Olivenstein, R., et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 184:8 (2010), 4531–4537.
143. [143] Tak, P.P., Firestein, G.S., NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:1 (2001), 7–11.
144. [144] Tasken, K., Aandahl, E.M., Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:1 (2004), 137–167.
145. [145] Reich K, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a Phase III, Randomized, Controlled Trial (ESTEEM 1). Abstract P8296 Presented at the 72nd Annual Meeting of the American Academy of Dermatology. Denver, CO, USA; March 21–25, 2014.
146. [146] FDA. FDA Approves Otezla to Treat Psoriatic Arthritis. 〈http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm390091.htm.〉 Accessed 20.06.14.
147. ® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis. 〈http://ir.celgene.com/releasedetail.cfm?releaseid=872240〉. Accessed 9.11.15.
148. [148] Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:9865 (2013), 451–460.
149. [149] Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:6 (2012), 495–507.
150. [150] Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:4 (2013), 253–261.
151. [151] van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:3 (2013), 559–570.
152. [152] van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., García Meijide, J.A., Wagner, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:6 (2012), 508–519.
153. [153] Garces, S., Demengeot, J., benito-Garcia, E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:12 (2013), 1947–1955.
154. [154] Gossec, L., Smolen, J.S., Gaujoux-Viala, C., Ash, Z., Marzo-Ortega, H., van der Heijde, D., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71:1 (2012), 4–12.
155. [155] Upchurch, K.S., Kay, J., Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 51:suppl 6 (2012), vi28–vi36.
156. [156] Moreland, L., Unmet needs in rheumatoid arthritis. Arthritis Res Ther 7:suppl 3 (2005), S2–S8.
157. [157] Heiberg, M.S., Koldingsnes, W., Mikkelsen, K., Rodevand, E., Kaufmann, C., Mowinckel, P., et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59:2 (2008), 234–240.
158. [158] Gottlieb, A.B., Langley, R.G., Strober, B.E., Papp, K.A., Klekotka, P., Creamer, K., et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 167:3 (2012), 649–657.
159. [159] Gustafson, C.J., Watkins, C., Hix, E., Feldman, S.R., Combination therapy in psoriasis: an evidence-based review. Am J Clin Dermatol 14:1 (2013), 9–25.
160. [160] Escande, H., Livideanu, C.B., Steiner, A., Lahfa, M., Marguery, M.C., Mazereeuw, J.H., et al. Incidence and risk factors for treatment failure with infliximab in psoriasis. J Eur Acad Dermatol Venereol 27:10 (2013), 1323–1324.
161. [161] Esposito, M., Gisondi, P., Cassano, N., Ferrucci, G., Del Giglio, M., Loconsole, F., et al. Survival rate of antitumour necrosis factor-a treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 169:3 (2013), 666–672.
162. [162] Gniadecki, R., Kragballe, K., Dam, T.N., Skov, L., Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 164:5 (2011), 1091–1096.
163. [163] Altobelli, E., Petrocelli, R., Maccarone, M., Altomare, G., Argenziano, G., Giannetti, A., et al. Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 19:3 (2009), 252–256.
164. [164] Curtis, J.R., Beukelman, T., Onofrei, A., Cassell, S., Greenberg, J.D., Kavanaugh, A., et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 69:1 (2010), 43–47.
165. [165] Helliwell, P.S., Taylor, W.J., Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs—comparison of drugs and adverse reactions. J Rheumatol 35:3 (2008), 472–476.
166. [166] Love, T.J., Zhu, Y., Zhang, Y., Wall-Burns, L., Ogdie, A., Gelfand, J.M., et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71:8 (2012), 1273–1277.
167. [167] Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:3 (2006), 692–701.
168. [168] Lacaille, D., Guh, D.P., Abrahamowicz, M., Anis, A.H., Esdaile, J.M., Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 59:8 (2008), 1074–1081.
169. [169] Bax, M., van Heemst, J., Huizinga, T.W., Toes, R.E., Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics 63:8 (2011), 459–466.
170. [170] Chandran, V., Schentag, C.T., Brockbank, J.E., Pellett, F.J., Shanmugarajah, S., Toloza, S.M., et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 68:5 (2009), 664–667.
171. [171] Duffin, K.C., Chandran, V., Gladman, D.D., Krueger, G.G., Elder, J.T., Rahman, P., Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 35:7 (2008), 1449–1453.
172. [172] Haroon, M., Winchester, R., Giles, J.T., Heffernan, E., Fitzgerald, O., Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 75:1 (2016), 155–162.
173. [173] Huffmeier, U., Uebe, S., Ekici, A.B., Bowes, J., Giardina, E., Korendowych, E., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42:11 (2010), 996–999.
174. [174] Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet, 4(3), 2008, e1000041.
175. [175] Nair, R.P., Duffin, K.C., Helms, C., Ding, J., Stuart, P.E., Goldgar, D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:2 (2009), 199–204.
176. [176] Pollock, R., Chandran, V., Barrett, J., Eder, L., Pellett, F., Yao, C., et al. Differential major histocompatibility complex class I chain-related A allele associations with skin and joint manifestations of psoriatic disease. Tissue Antigens 77:6 (2011), 554–561.
177. [177] Rahman, P., Siannis, F., Butt, C., Farewell, V., Peddle, L., Pellett, F., et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 65:7 (2006), 919–923.
178. [178] Stastny, P., Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 298:16 (1978), 869–871.
179. [179] van der Woude, D., Lie, B.A., Lundstrom, E., Balsa, A., Feitsma, A.L., Houwing-Duistermaat, J.J., et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 62:5 (2010), 1236–1245.
180. [180] Winchester, R., Minevich, G., Steshenko, V., Kirby, B., Kane, D., Greenberg, D.A., et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 64:4 (2012), 1134–1144.
181. [181] Pitzalis, C., Kelly, S., Humby, F., New learnings on the pathophysiology of RA from synovial biopsies. Curr Opin Rheumatol 25:3 (2013), 334–344.
182. [182] Ademowo, O.S., Hernandez, B., Collins, E., Rooney, C., Fearon, U., van Kuijk, A.W., et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis 75:1 (2016), 234–241.
183. [183] Emery, P., Dorner, T., Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 70:12 (2011), 2063–2070.
184. [184] Quartuccio, L., Fabris, M., Salvin, S., Atzeni, F., Saracco, M., Benucci, M., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 48:12 (2009), 1557–1559.
185. [185] Trocme, C., Marotte, H., Baillet, A., Pallot-Prades, B., Garin, J., Grange, L., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 68:8 (2009), 1328–1333.
186. [186] Thurlings, R.M., Boumans, M., Tekstra, J., van Roon, J.A., Vos, K., van Westing, D.M., et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 62:12 (2010), 3607–3614.
187. [187] Vital, E.M., Dass, S., Rawstron, A.C., Buch, M.H., Goeb, V., Henshaw, K., et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62:5 (2010), 1273–1279.
188. [188] Abildtrup, M., Kingsley, G.H., Scott, D.L., Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol 42:5 (2015), 760–770.
189. [189] Obry, A., Lequerre, T., Hardouin, J., Boyer, O., Fardellone, P., Philippe, P., et al. Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS One, 9(12), 2014, e115800.
190. [190] Choi, I.Y., Gerlag, D.M., Holzinger, D., Roth, J., Tak, P.P., From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis. PLoS One, 9(8), 2014, e106253.
191. [191] Cheng, T., Wang, M., Chen, Z., Eisenberg, R.A., Zhang, Y., Zou, Y., et al. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese. Chin Med J (Engl) 127:16 (2014), 2894–2899.
192. [192] Duroux-Richard, I., Pers, Y.M., Fabre, S., Ammari, M., Baeten, D., Cartron, G., et al. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm, 2014, 2014, 342524.
193. [193] Shimamoto, K., Ito, T., Ozaki, Y., Amuro, H., Tanaka, A., Nishizawa, T., et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 40:7 (2013), 1074–1081.
194. [194] Misko, T.P., Radabaugh, M.R., Highkin, M., Abrams, M., Friese, O., Gallavan, R., et al. Characterization of nitrotyrosine as a biomarker for arthritis and joint injury. Osteoarthritis Cartilage 21:1 (2013), 151–156.
195. [195] O'Rielly, D.D., Roslin, N.M., Beyene, J., Pope, A., Rahman, P., TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 9:3 (2009), 161–167.
196. [196] Gallo, E., Cabaleiro, T., Roman, M., Solano-Lopez, G., Abad-Santos, F., Garcia-Diez, A., et al. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol 169:4 (2013), 819–829.
197. [197] Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 169:2 (2013), 458–463.
198. [198] DʼErme, A.M., Wilsmann-Theis, D., Wagenpfeil, J., Holzel, M., Ferring-Schmitt, S., Sternberg, S., et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 135:4 (2015), 1025–1032.